

# Accepted Manuscript

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

J.G. Abraldes, C. Villanueva, C. Aracil, J. Turnes, M. Hernandez-Guerra, J. Genesca, M. Rodriguez, J. Castellote, J.C. García-Pagán, F. Torres, J.L. Calleja, A. Albillos, J. Bosch, for the BLEPS study group

PII: S0016-5085(16)00043-3  
DOI: [10.1053/j.gastro.2016.01.004](https://doi.org/10.1053/j.gastro.2016.01.004)  
Reference: YGAST 60231

To appear in: *Gastroenterology*  
Accepted Date: 8 January 2016

Please cite this article as: Abraldes J, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, Rodriguez M, Castellote J, García-Pagán J, Torres F, Calleja J, Albillos A, Bosch J, for the BLEPS study group, Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis, *Gastroenterology* (2016), doi: 10.1053/j.gastro.2016.01.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

**Authors: Abraldes JG<sup>1\*</sup>, Villanueva C<sup>2\*</sup>, Aracil C<sup>3</sup>, Turnes J<sup>4</sup>, Hernandez-Guerra M<sup>5</sup>, Genesca J<sup>6</sup>, Rodriguez M<sup>7</sup>, Castellote J<sup>8</sup>, García-Pagán JC<sup>1</sup>, Torres F<sup>9</sup>, Calleja JL<sup>10</sup>, Albillos A<sup>11</sup>, Bosch J<sup>1</sup> for the BLEPS study group.**

## **\*Share first authorship**

1. Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic-IDIBAPS, University of Barcelona, CIBEREHD, Spain. 2. Department of Gastroenterology. Hospital de Sant Pau, Barcelona. Autonomous University, Barcelona, CIBEREHD. Spain. 3. Servicio de Gastroenterología, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomedica (IRBLleida), Lleida, Spain. 4. Department of Gastroenterology, Complejo Hospitalario Universitario de Pontevedra - Instituto de Investigación Biomédica (IBI), Pontevedra, Spain. 5. Gastroenterology Department, University Hospital of the Canary Islands, Tenerife, Spain. 6. Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain. 7. Liver Unit, Hospital Universitario Central de Asturias, Oviedo, Spain. 8. Unidad de Hepatología. Servicio de Aparato Digestivo. IDIBELL: Hospital Universitari de Bellvitge, Badalona, Spain. 9. Biostatistics and Data Management Core Facility, IDIBAPS, Hospital Clínic Barcelona, Spain and Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 10. Liver Unit. Hospital U. Puerta de Hierro. Universidad Autonoma de Madrid, CIBEREHD, Spain. 11. Department of Gastroenterology, Hospital Universitario Ramón y Cajal, IRYCIS, University of Alcalá, Madrid, CIBEREHD, Spain.

Address correspondence to Dr Jaime Bosch, Hepatic Hemodynamic Laboratory, Hospital Clínic, C.Villarroel 170, 08036 Barcelona, Spain. E-mail address: [jbosch@clinic.ub.es](mailto:jbosch@clinic.ub.es); or Dr Juan G Abraldes, current address: 1-38 Zeidler Ledcor Centre, Division of Gastroenterology. University of Alberta, Edmonton, AB, T6G 2X8, Canada. e-mail address: [juan.g.abraldes@ualberta.ca](mailto:juan.g.abraldes@ualberta.ca).

All authors declare that they do not have any conflict of interest with any company whose product is pertinent to the submitted manuscript or with a company making a competing product.

The Spanish Ministry of Health funded the trial through a competitive peer-reviewed grant. The funding agency had no role in the collection, analysis or interpretation of the data.

Download English Version:

<https://daneshyari.com/en/article/6092577>

Download Persian Version:

<https://daneshyari.com/article/6092577>

[Daneshyari.com](https://daneshyari.com)